Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIC - WACC | 22.8% | 90.7% | 78.8% | 3.6% | (34.2%) | 2.4% | 24.8% | 47.3% | 46.4% | 23.9% | 46.1% | 34.8% | 82.6% | 45.5% | 54.5% | (15.6%) | 37.8% | 34.6% | 58.0% | 57.9% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month ROIC - WACC is 63.5%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual ROIC - WACC for United Therapeutics Corporation have been 56.8% over the past three years, and 49.7% over the past five years.
As of today, United Therapeutics Corporation's ROIC - WACC is 63.5%, which is higher than industry median of (127.8%). It indicates that United Therapeutics Corporation's ROIC - WACC is Good.